Anebulo Pharmaceuticals, Inc. (ANEB) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- Oil settles $3 higher on Yanbu disruption, Saudi cargo cancellations
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
- JPMorgan Downgrades Rapid7 (RPD) to Underweight
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
February 10, 2023 8:38 AM ESTAUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended December 31, 2022 and recent updates.
Second Quarter Fiscal Year 2023 and Subsequent Highlights:
Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evaluating ANEB-001s potential in treating acute cannabinoid intoxication (ACI). Preliminary data showed that a single 10 mg oral dose of ANEB-001 reduced key symptoms... More